CRISPR-Cas System : The Current and Emerging Translational Landscape
CRISPR-Cas technology has rapidly changed life science research and human medicine. The ability to add, remove, or edit human DNA sequences has transformative potential for treating congenital and acquired human diseases. The timely maturation of the cell and gene therapy ecosystem and its seamless integration with CRISPR-Cas technologies has enabled the development of therapies that could potentially cure not only monogenic diseases such as sickle cell anemia and muscular dystrophy, but also complex heterogenous diseases such as cancer and diabetes. Here, we review the current landscape of clinical trials involving the use of various CRISPR-Cas systems as therapeutics for human diseases, discuss challenges, and explore new CRISPR-Cas-based tools such as base editing, prime editing, CRISPR-based transcriptional regulation, CRISPR-based epigenome editing, and RNA editing, each promising new functionality and broadening therapeutic potential. Finally, we discuss how the CRISPR-Cas system is being used to understand the biology of human diseases through the generation of large animal disease models used for preclinical testing of emerging therapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cells - 12(2023), 8 vom: 07. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bhokisham, Narendranath [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Base editors |
|---|
| Anmerkungen: |
Date Completed 17.05.2023 Date Revised 19.05.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/cells12081103 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356926680 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356926680 | ||
| 003 | DE-627 | ||
| 005 | 20231226071508.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cells12081103 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356926680 | ||
| 035 | |a (NLM)37190012 | ||
| 035 | |a (PII)1103 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bhokisham, Narendranath |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CRISPR-Cas System |b The Current and Emerging Translational Landscape |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2023 | ||
| 500 | |a Date Revised 19.05.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a CRISPR-Cas technology has rapidly changed life science research and human medicine. The ability to add, remove, or edit human DNA sequences has transformative potential for treating congenital and acquired human diseases. The timely maturation of the cell and gene therapy ecosystem and its seamless integration with CRISPR-Cas technologies has enabled the development of therapies that could potentially cure not only monogenic diseases such as sickle cell anemia and muscular dystrophy, but also complex heterogenous diseases such as cancer and diabetes. Here, we review the current landscape of clinical trials involving the use of various CRISPR-Cas systems as therapeutics for human diseases, discuss challenges, and explore new CRISPR-Cas-based tools such as base editing, prime editing, CRISPR-based transcriptional regulation, CRISPR-based epigenome editing, and RNA editing, each promising new functionality and broadening therapeutic potential. Finally, we discuss how the CRISPR-Cas system is being used to understand the biology of human diseases through the generation of large animal disease models used for preclinical testing of emerging therapeutics | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a CRISPR animal models | |
| 650 | 4 | |a CRISPR-Cas | |
| 650 | 4 | |a base editors | |
| 650 | 4 | |a clinical study | |
| 650 | 4 | |a gene editing | |
| 650 | 4 | |a prime editors | |
| 650 | 4 | |a translational research | |
| 700 | 1 | |a Laudermilch, Ethan |e verfasserin |4 aut | |
| 700 | 1 | |a Traeger, Lindsay L |e verfasserin |4 aut | |
| 700 | 1 | |a Bonilla, Tonya D |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Estevez, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Becker, Jordan R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cells |d 2011 |g 12(2023), 8 vom: 07. Apr. |w (DE-627)NLM227066421 |x 2073-4409 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:8 |g day:07 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cells12081103 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 8 |b 07 |c 04 | ||